Navigation Links
Medical research is essential to improving the economy and bettering lives
Date:5/6/2008

Washington, DC (Monday, May 5, 2008) Health care in the United States is expensive, but its funding is crucial because it also is a major contributor to the economy and can better lives, according to an essay appearing in the June 2008 issue of the Journal of the American Society Nephrology (JASN). Because of the cost of health care, this is not time to shrink the budget at the National Institutes of Health, which funds medical research that leads to potentially curative therapy.

As the US population increases, health care costs are sure to rise. To help stem rising health care costs, government officials are taking money away from Medicare and Medicaid programs, and budget planners are reducing the funds used to support medical science. But experts question this strategy, noting that health care employs a large segment of the national workforce (and is, therefore, a fundamental feature of the economy) and medical research is a critical enterprise that over the long run will provide more affordable health careso called high technology, as Lewis Thomas once phrased it.

Dr. Eric Neilson, Editor-in-Chief of the Journal of the American Society Nephrology and Chair of the Department of Medicine at the Vanderbilt University School of Medicine in Nashville, TN, addresses these concerns in JASN, pointing to clear examples of how investments in health care and medical research can pay off. He notes that the human papillomavirus vaccine, the antibiotic elimination of H. pyloriinduced peptic ulcer disease, and the all-trans-retinoic acid cure of promyelocytic leukemia are all cost-effective advances that have improved lives and lowered costs. Of course, these advances took years to achieve, and long-term robust funding of research was necessary for their potential to be realized.

Dr. Neilson admits that many aspects of health care are not cost-effectivefor example, the sluggish economic productivity of the doctor-patient relationship is a
'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. KePROs Chief Medical Officer to Deliver Clinical Keynote Address
2. ABQAURP Hosts Third Annual Medical Management Conference in Orlando
3. Warren F. Muth, MD, to Serve as President of Ohio State Medical Association
4. BioForm Medical Announces Extension of Lock-Up Period
5. Federation of State Medical Boards Takes Interim Steps Toward Maintenance of Licensure Model Policy
6. Lombard Makes Investment in The Medical City, a Leading Philippine Hospital and Healthcare Provider
7. Game-Based Technology to Meet Demand for Improved Medical Teaching and Training
8. New Medical Technology is Changing the Face of Wrinkle Treatment
9. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
10. China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits
11. Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medical research is essential to improving the economy and bettering lives
Medical research is essential to improving the economy and bettering lives
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4
Other Medicine Technology:Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5